Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20139479 | 0.98 | MAPT (0.54) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL8316368 | 0.90 | HRH3 (0.58) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15569388 | 0.90 | MAPT (0.62) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4172495 | 0.86 | MAPT (0.58) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15956633 | 0.85 | MAPT (0.57) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5071255 | 0.85 | MAPT (0.57) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL30924929 | 0.83 | MAPT (0.55) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL30414662 | 0.83 | MAPT (0.55) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL853489 | 0.83 | MAPT (0.55) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL17284582 | 0.83 | MAPT (0.55) | MAPTKDM4ELMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383854-A1 | PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES | HOVIONE FARMACIENCIA SA (PT) | 2024-11-21 | — | — | US | claimed |
| CN-112645945-B | Preparation method of Wumei ammonium bromide intermediate | 上海谷森医药有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-20240383854-A1 | PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES | HOVIONE FARMACIENCIA SA (PT) | 2024-11-21 | — | — | US | disclosed |
| EP-4392411-A1 | PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES | Hovione Farmaciencia SA (PT) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023030667-A1 | PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES | HOVIONE SCIENTIA (IE) | 2023-03-09 | — | — | WO | disclosed |
| CN-115385906-A | Method for preparing umeclidinium bromide | 好利安科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-11427584-B2 | Process for the preparation of umeclidinium bromide | HOVIONE SCIENTIA LIMITED (IE) | 2022-08-30 | — | — | US | disclosed |
| US-11427584-B2 | Process for the preparation of umeclidinium bromide | HOVIONE SCIENTIA LIMITED (IE) | 2022-08-30 | — | — | US | disclosed |
| JP-2022088623-A | PROCESS FOR PREPARATION OF UMECLIDINIUM BROMIDE | ホビオネ サイエンティア リミテッド | 2022-06-14 | — | — | JP | disclosed |
| CN-112645945-B | Preparation method of Wumei ammonium bromide intermediate | 上海谷森医药有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-7498440-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7488827-B2 | Muscle relaxants; respiratory system disorders; asthma;COPD; emphysema; bronchitis | GLAXO GROUP LIMITED (GB) | 2009-02-10 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070173646-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| EP-1747219-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS FIELD OF THE INVENTION | GLAXO GROUP LIMITED (GB) | 2007-01-31 | — | — | EP | disclosed |
| EP-1740177-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005112644-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005104745-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | MAPT 4036/4885KDM4E 3835/4885LMNA 4137/4885 |
| US-20070173646-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | MAPT 4036/4885KDM4E 3835/4885LMNA 4137/4885 |
| US-11427584-B2 | Process for the preparation of umeclidinium bromide | CLIC4, RPL4, UROD | MAPT 825/4885KDM4E 6/4885LMNA 1528/4885 |
| US-20240383854-A1 | PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES | ETFB, TOP2B, MGMT | MAPT 4023/4885KDM4E 381/4885LMNA 1506/4885 |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | MAPT 4036/4885KDM4E 3835/4885LMNA 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.